What’s Propelling Tapimmune Inc (NASDAQ:TPIV) After Higher Shorts Reported?

October 13, 2018 - By Michael Collier

TapImmune, Inc. (NASDAQ:TPIV) Logo

The stock of Tapimmune Inc (NASDAQ:TPIV) registered an increase of 4.75% in short interest. TPIV’s total short interest was 876,900 shares in October as published by FINRA. Its up 4.75% from 837,100 shares, reported previously. With 124,600 shares average volume, it will take short sellers 7 days to cover their TPIV’s short positions.

The stock decreased 5.71% or $0.45 during the last trading session, reaching $7.43. About 215,382 shares traded or 3.25% up from the average. TapImmune, Inc. (NASDAQ:TPIV) has risen 218.46% since October 13, 2017 and is uptrending. It has outperformed by 202.84% the S&P500.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company has market cap of $101.87 million. It specializes in the development of immunotherapies targeting women??s cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. It currently has negative earnings. The company??s peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient??s killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

More important recent TapImmune, Inc. (NASDAQ:TPIV) news were published by: Prnewswire.com which released: “TapImmune to Present at Two Upcoming Investor Conferences” on September 25, 2018, also Benzinga.com published article titled: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs”, Schaeffersresearch.com published: “Penny Stock Near the Top of the Nasdaq” on October 10, 2018. More interesting news about TapImmune, Inc. (NASDAQ:TPIV) was released by: Seekingalpha.com and their article: “TapImmune’s Phase 2 study of TPIV110 receives $11M grant from US Department of Defense Grant” with publication date: October 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>